Nivolumab (n-40) | Nivolumab + Ipilimumab (n=46)a | |
---|---|---|
ORR, % | 18 | 17 |
Complete response, % | 0 | 2.2 |
Partial response, % | 18 | 15 |
Stable disease,b % | 20 | 37 |
Disease control rate, % | 38 | 54 |
Progressive disease, % | 53c | 37 |
Death prior to first response assessment, % | 10 | 6.5d |
Not evaluable (no tumor assessment follow-up), % | 0 | 2.2e |
Median time to objective response (months) | 1.6 | 2.2 |
Median DOR, months (95% CI) Range | NR 4.1-11+ | 6.9 (1.5 NR) 1,5-11,1+ |